Adalimumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Juvenile Rheumatoid Arthritis
Conditions
Juvenile Rheumatoid Arthritis
Trial Timeline
May 1, 2008 → Sep 1, 2011
NCT ID
NCT00690573About Adalimumab
Adalimumab is a phase 3 stage product being developed by Eisai for Juvenile Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00690573. Target conditions include Juvenile Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01243671 | Phase 3 | Completed |
| NCT00690573 | Phase 3 | Completed |
| NCT00667355 | Phase 3 | Completed |
| NCT00445432 | Phase 2/3 | Completed |
| NCT00603993 | Phase 3 | Completed |
| NCT00235872 | Phase 3 | Completed |
| NCT00235833 | Phase 2 | Completed |
Competing Products
20 competing products in Juvenile Rheumatoid Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX-200 + Placebo | Polaryx Therapeutics | Phase 3 | 69 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| Abatacept | Ono Pharmaceutical | Phase 3 | 77 |
| Ixekizumab + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Tocilizumab | Eli Lilly | Phase 3 | 77 |
| adalimumab + Methotrexate | AbbVie | Pre-clinical | 23 |
| Upadacitinib | AbbVie | Phase 1 | 33 |
| Upadacitinib + Tocilizumab | AbbVie | Phase 3 | 77 |
| Adalimumab + Risankizumab | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Phase 3 | 77 |
| naproxen + esomeprazole | AstraZeneca | Phase 1 | 33 |
| Alendronate (Fosamax) | Merck | Pre-clinical | 23 |
| canakinumab | Novartis | Phase 3 | 77 |
| Secukinumab | Novartis | Phase 1 | 33 |
| ACZ885 150 mg (Canakinumab) | Novartis | Phase 3 | 77 |